Pfizer enters 2026 facing earnings pressure from COVID revenue collapse and acquisition-related dilution. Click here to read ...
By the beginning of 2025, it was clear the GLP-1 drugs were going to remain a major part of the industry. Pfizer used its presentation at the 43 rd JP Morgan Healthcre Conference to detail plans to ...
20hon MSNOpinion
'When I grow up, I want to be like you': Remembering Morris Kahn's most productive years
Founder of the Genesis Prize Stan Polovets on why your seventies and eighties – and even nineties – can be your most ...
Pfizer faces another year of revenue decline in 2026, as Covid and loss-of-exclusivity headwinds weigh on top line growth.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback